Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Leidos
LDOS
$17.6B
| $36.1M | 0.01% |
200,061
-115,751
| -37% | -$21.9M |
|
927
PUT
Arista Networks
ANET
$247B
| $36M | 0.01% |
274,800
+80,600
| +42% | +$11.1M |
|
|
928
CALL
Kenvue
KVUE
$36.4B
| $36M | 0.01% |
2,085,300
-3,187,600
| -60% | -$52.1M |
|
929
Tyler Technologies
TYL
$13.2B
| $36M | 0.01% |
79,217
-6,249
| -7% | -$2.98M |
|
930
Neurocrine Biosciences
NBIX
$16.5B
| $35.8M | 0.01% |
252,241
-51,737
| -17% | -$7.5M |
|
931
Yum China
YUMC
$16.2B
| $35.7M | 0.01% |
746,931
+202,486
| +37% | +$9.28M |
|
932
PUT
Super Micro Computer
SMCI
$20.3B
| $35.7M | 0.01% |
1,218,200
+460,900
| +61% | +$19M |
|
933
Align Technology
ALGN
$12.3B
| $35.4M | 0.01% |
226,967
-22,457
| -9% | -$3.22M |
|
934
PUT
Spotify
SPOT
$102B
| $35.4M | 0.01% |
+61,000
| New | +$38.1M |
|
935
CALL
Expedia Group
EXPE
$38.7B
| $35.4M | 0.01% |
+125,000
| New | +$30.9M |
|
936
Camden Property Trust
CPT
$10.9B
| $35.4M | 0.01% |
321,346
+2,820
| +0.9% | +$293K |
|
937
Rio Tinto
RIO
$164B
| $35.4M | 0.01% |
441,921
+284,675
| +181% | +$20.5M |
|
938
Exelixis
EXEL
$12.8B
| $35.3M | 0.01% |
805,051
+72,365
| +10% | +$2.99M |
|
939
Celsius Holdings
CELH
$6.89B
| $35.3M | 0.01% |
771,169
+491,363
| +176% | +$24.8M |
|
940
PUT
Darden Restaurants
DRI
$24.8B
| $35.2M | 0.01% |
191,500
+2,800
| +1% | +$510K |
|
941
Norwegian Cruise Line
NCLH
$8.54B
| $35.1M | 0.01% |
1,571,340
-300,376
| -16% | -$6.34M |
|
942
Natera
NTRA
$45.8B
| $35M | 0.01% |
152,908
-32,029
| -17% | -$6.68M |
|
943
Ball Corp
BALL
$16.6B
| $35M | 0.01% |
661,052
-167,118
| -20% | -$8.22M |
|
944
CALL
ScottsMiracle-Gro
SMG
$3.6B
| $35M | 0.01% |
600,000
| – | – |
|
945
PUT
Fortinet
FTNT
$120B
| $34.9M | 0.01% |
+440,000
| New | +$36.5M |
|
|
HOLX
946
DELISTED
Hologic
HOLX
| $34.9M | 0.01% |
469,020
+1,206
| +0.3% | +$88.1K |
|
947
Snap-on
SNA
$21.4B
| $34.9M | 0.01% |
101,295
-19,793
| -16% | -$6.77M |
|
|
948
PUT
Gilead Sciences
GILD
$169B
| $34.9M | 0.01% |
284,100
| – | – |
|
949
AES
AES
$10.5B
| $34.9M | 0.01% |
2,431,251
-872,250
| -26% | -$12.3M |
|
950
PUT
Mercado Libre
MELI
$97.4B
| $34.8M | 0.01% |
17,300
+17,000
| +5,667% | +$35.7M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.